XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Statements of Cash Flows - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash Flows From Operating Activities    
Net loss $ (10,922,101) $ (5,739,366)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 546,232 819,064
Depreciation of property and equipment 247,728 63,119
Amortization of debt discount 184,207 149,490
Write-off of property and equipment 85,051  
Write-down of inventories to net realizable value 198,034 0
Provision for defective clinical supply settlement 100,000  
Non-cash rent expense 127,904 133,907
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (154,486) (212,025)
License fee and expense reimbursements receivables 35,788 210,109
Deferred clinical supply costs 375,944 (1,067,714)
Inventories (567,598)  
Accounts payable 392,100 (26,207)
Accrued compensation (830,327) (1,110,002)
Accrued expenses and other current liabilities 363,828 (42,933)
Lease liabilities (74,101) (136,150)
Net Cash Used In Operating Activities (9,891,747) (6,958,708)
Cash Flows From Investing Activities    
Purchases of property and equipment (114,105) (920,865)
Vendor deposits for property and equipment   82,813
Net Cash Used In Investing Activities (114,105) (838,052)
Cash Flows From Financing Activities    
Proceeds from sale of common stock in At the Market offering 3,293,347 3,607,827
Payment of issuance costs for At the Market offering (98,800) (108,235)
Repayments of notes payable (61,646) (100,030)
Net Cash Provided By Financing Activities 3,132,901 3,399,562
Net Decrease in Cash and Cash Equivalents (6,872,951) (4,397,198)
Cash and Cash Equivalents - Beginning of Year 14,849,057 22,863,520
Cash and Cash Equivalents - End of Year 7,976,106 18,466,322
Supplemental Disclosure of Cash Flow Information:    
Interest 494,451 304,512
Supplemental Disclosure of Non-Cash Investing and Financing Activities    
Purchase of insurance policy financed by note payable 505,050 609,140
Accrual for intangible asset milestone obligations 4,000,000  
Reclassification of deferred clinical supply costs to inventories $ 3,034,498  
Right-of-use assets obtained in exchange for lease liabilities   350,473
Cashless exercise of stock options   $ 2